Inantol

Fluticasone propionate / Salmeterol, the active ingredient in Inantol, is an inhaled corticosteroid / long‑acting β2‑agonist combination presented as an inhalation aerosol for inhalation use. It provides maintenance therapy for asthma and chronic obstructive pulmonary disease in adult patients. GNH USA supplies Inantol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inantol is used as a maintenance inhaler targeting chronic respiratory disease pathways, improving lung function and reducing exacerbations.

Asthma: helps control symptoms and prevents flare‑ups when used regularly. Chronic obstructive pulmonary disease (COPD): reduces breathlessness and frequency of exacerbations. Bronchospasm prevention: provides long‑acting bronchodilation to maintain open airways in patients requiring combination therapy.

Inhaled corticosteroid/long‑acting β2‑agonist therapy can cause a range of adverse reactions.

Common Side Effects: - Oral thrush or candidiasis - Hoarseness or voice changes - Cough or throat irritation - Headache - Nasal congestion - Dry mouth

Serious or Rare Side Effects: - Paradoxical bronchospasm - Adrenal suppression with systemic effects - Severe allergic reactions (anaphylaxis) - Cardiac arrhythmias or tachycardia - Decreased bone mineral density with long‑term use - Pneumonia in COPD patients

When prescribing Inantol, clinicians should consider several safety measures.

Assess infection risk: monitor for oral candidiasis and treat promptly. Monitor growth in children: long‑term corticosteroid exposure may affect growth velocity. Avoid abrupt discontinuation: taper to prevent adrenal insufficiency. Use mouth rinse after inhalation: reduces local steroid deposition. Check for hypersensitivity: discontinue if allergic reaction occurs. Store at room temperature: keep in original container, protect from moisture and heat.

Inantol may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) may increase systemic steroid exposure. - Non‑selective β‑blockers can blunt bronchodilator response. - Diuretics may exacerbate β2‑agonist‑induced hypokalemia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole) may modestly raise drug levels. - Ritonavir and other protease inhibitors can increase exposure. - Anticholinergic agents may add to anticholinergic load, affecting airway tone.